Akorn Shares Outstanding 2006-2018 | AKRX

Akorn shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Akorn shares outstanding for the quarter ending June 30, 2018 were 0.125B, a 0.11% increase year-over-year.
  • Akorn 2017 shares outstanding were 0.125B, a 0.8% decline from 2016.
  • Akorn 2016 shares outstanding were 0.126B, a 0.03% increase from 2015.
  • Akorn 2015 shares outstanding were 0.126B, a 14.76% increase from 2014.
Akorn Annual Shares Outstanding
(Millions of Shares)
2017 125
2016 126
2015 126
2014 110
2013 114
2012 111
2011 104
2010 99
2009 90
2008 89
2007 87
2006 74
2005 26
Akorn Quarterly Shares Outstanding
(Millions of Shares)
Q2 2018 125
Q1 2018 125
Q4 2017 125
Q3 2017 125
Q2 2017 125
Q1 2017 125
Q4 2016 126
Q3 2016 126
Q2 2016 126
Q1 2016 126
Q4 2015 126
Q3 2015 126
Q2 2015 126
Q1 2015 125
Q4 2014 110
Q3 2014 105
Q2 2014 103
Q1 2014 117
Q4 2013 114
Q3 2013 114
Q2 2013 112
Q1 2013 112
Q4 2012 111
Q3 2012 111
Q2 2012 111
Q1 2012 109
Q4 2011 104
Q3 2011 104
Q2 2011 105
Q1 2011 104
Q4 2010 99
Q3 2010 101
Q2 2010 93
Q1 2010 93
Q4 2009 90
Q3 2009 90
Q2 2009 90
Q1 2009 90
Q4 2008 89
Q3 2008 90
Q2 2008 89
Q1 2008 89
Q4 2007 87
Q3 2007 88
Q2 2007 87
Q1 2007 86
Q4 2006 74
Q3 2006 76
Q2 2006 75
Q1 2006 75
Q4 2005 26
Q3 2005 26
Q2 2005 26
Q1 2005 25
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.679B $0.841B
Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. They specialize in difficult-to-manufacture sterile and non-sterile dosage forms including: ophthalmics, injectables, oral liquids, otics, topicals, inhalants, and nasal sprays. Akorn markets its products to retail pharmacies, ophthalmologists, optometrists, physicians, veterinarians, hospitals, clinics, wholesalers, distributors, group purchasing organizations, and government agencies. Their strategy is focused on continuing to strengthen our leadership position in the development and marketing of specialized generic and branded pharmaceuticals, over-the-counter (`OTC`) drug products and animal health products.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $63.826B 10.95
Teva Pharmaceutical Industries (TEVA) Israel $25.056B 7.00
Mylan (MYL) United Kingdom $19.715B 8.39
Bausch Health Cos (BHC) Canada $8.415B 6.27
Dr Reddy's Laboratories (RDY) India $6.003B 26.82
Supernus Pharmaceuticals (SUPN) United States $2.501B 26.76
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.470B 4.20
Assembly Biosciences (ASMB) United States $0.885B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.865B 124.67
Homology Medicines (FIXX) United States $0.764B 0.00
CymaBay Therapeutics (CBAY) United States $0.714B 0.00
Voyager Therapeutics (VYGR) United States $0.585B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.512B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.484B 0.00
Corium (CORI) United States $0.323B 0.00
Teligent (TLGT) United States $0.202B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.139B 0.00
Sol-Gel Technologies (SLGL) Israel $0.135B 0.00
Aevi Genomic Medicine (GNMX) United States $0.080B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.065B 0.00
Evoke Pharma (EVOK) United States $0.054B 0.00
Versartis (VSAR) United States $0.052B 0.00
Acasti Pharma (ACST) Canada $0.021B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.012B 0.00
Agile Therapeutics (AGRX) United States $0.012B 0.00
China Pharma Holdings (CPHI) China $0.009B 0.00